Positron emission tomography imaging for gastroesophageal junction tumors

Seminars in Radiation Oncology

Volumn 23, Issue 1, 2013, Pages 10-15

  Wu, Abraham J ^a   Goodman, Karyn A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPIC ECHOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS TUMOR; EVENT FREE SURVIVAL; GASTROINTESTINAL ENDOSCOPY; HUMAN; INDUCTION CHEMOTHERAPY; INTERMETHOD COMPARISON; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER TUMOR; METASTASIS; MULTICENTER STUDY (TOPIC); OCCULT CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH TUMOR; TREATMENT FAILURE; TREATMENT RESPONSE;

ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; POSITRON-EMISSION TOMOGRAPHY; STOMACH NEOPLASMS;

EID: 84874445597     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.09.001     Document Type: Article

References (52)

1. Ajani J.A., Barthel J.S., Bentrem D.J., et al. Esophageal and esophagogastric junction cancers. J Natl Compr Cancer Netw 2011, 9:830-887.
2. Downey R.J., Akhurst T., Ilson D., et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 2003, 21:428-432.
3. Flamen P., Lerut A., Van Cutsem E., et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000, 18:3202-3210.
4. Heeren P.A., Jager P.L., Bongaerts F., et al. Detection of distant metastases in esophageal cancer with (18)F-FDG PET. J Nucl Med 2004, 45:980-987.
5. Kato H., Miyazaki T., Nakajima M., et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005, 103:148-156.
6. Roedl J.B., Blake M.A., Holalkere N.S., et al. Lymph node staging in esophageal adenocarcinoma with PET-CT based on a visual analysis and based on metabolic parameters. Abdom Imaging 2009, 34:610-617.
7. Luketich J.D., Friedman D.M., Weigel T.L., et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999, 68:1133-1136. discussion 1136-1137.
8. Yoon H.H., Lowe V.J., Cassivi S.D., et al. The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. Gastroenterol Clin North Am 2009, 38:105-120. ix.
9. Dassen A.E., Lips D.J., Hoekstra C.J., et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 2009, 35:449-455.
10. Mukai K., Ishida Y., Okajima K., et al. Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006, 9:192-196.
11. Stahl A., Ott K., Weber W.A., et al. FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003, 30:288-295.
12. Ott K., Herrmann K., Schuster T., et al. Molecular imaging of proliferation and glucose utilization: Utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 2011, 18:3316-3323.
13. Bakheet S.M., Amin T., Alia A.G., et al. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med 1999, 24:995-997.
14. Koga H., Sasaki M., Kuwabara Y., et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003, 17:733-738.
15. van Westreenen H.L., Westerterp M., Bossuyt P.M., et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004, 22:3805-3812.
16. Shimizu S., Hosokawa M., Itoh K., et al. Can hybrid FDG-PET/CT detect subclinical lymph node metastasis of esophageal cancer appropriately and contribute to radiation treatment planning?. A comparison of image-based and pathological findings. Int J Clin Oncol 2009, 14:421-425.
17. Rizk N., Downey R.J., Akhurst T., et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006, 81:1076-1081.
18. Rizk N.P., Tang L., Adusumilli P.S., et al. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009, 4:875-879.
19. Shenfine J., Barbour A.P., Wong D., et al. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. Dis Esophagus 2009, 22:668-675.
20. Kato H., Nakajima M., Sohda M., et al. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 2009, 115:3196-3203.
21. Pan L., Gu P., Huang G., et al. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009, 21:1008-1015.
22. Omloo J.M., van Heijl M., Hoekstra O.S., et al. FDG-PET parameters as prognostic factor in esophageal cancer patients: A review. Ann Surg Oncol 2011, 18:3338-3352.
23. Chatterton B.E., Ho Shon I., Baldey A., et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: Results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009, 36:354-361.
24. Omloo J.M., Sloof G.W., Boellaard R., et al. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy 2008, 40:464-471.
25. Suzuki A., Xiao L., Hayashi Y., et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 2011, 117:4823-4833.
26. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058-3065.
27. Ott K., Weber W.A., Lordick F., et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006, 24:4692-4698.
28. Wieder H.A., Beer A.J., Lordick F., et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med 2005, 46:2029-2034.
29. Ilson D.H., Minsky B.D., Ku G.Y., et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer 2012, 118:2820-28277.
30. Kauppi J.T., Oksala N., Salo J.A., et al. Locally advanced esophageal adenocarcinoma: Response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol 2012, 51:636-644.
31. Klaeser B., Nitzsche E., Schuller J.C., et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: Results of a prospective multi-center trial (SAKK 75/02). Onkologie 2009, 32:724-730.
32. Flamen P., Van Cutsem E., Lerut A., et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002, 13:361-368.
33. Swisher S.G., Erasmus J., Maish M., et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004, 101:1776-1785.
34. Javeri H., Xiao L., Rohren E., et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009, 115:5184-5192.
35. Vallböhmer D., Hölscher A.H., Dietlein M., et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009, 250:888-894.
36. Wieder H.A., Brücher B.L., Zimmermann F., et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004, 22:900-908.
37. Gillham C.M., Lucey J.A., Keogan M., et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006, 95:1174-1179.
38. van Heijl M., Omloo J.M., van Berge Henegouwen M.I., et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 2011, 253:56-63.
39. Lordick F., Ott K., Krause B.J., et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007, 8:797-805.
40. zum Büschenfelde C.M., Herrmann K., Schuster T., et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial. J Nucl Med 2011, 52:1189-1196.
41. Lorenzen S., von Gall C., Stange A., et al. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the oesophago-gastric junction (AEG): The Heidelberg imaging program in cancer of the oesophago-gastric junction during neoadjuvant treatment: HICON trial. BMC Cancer 2011, 11:266.
42. PET scan imaging in assessing response in patients with esophageal cancer receiving combination chemotherapy ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01333033.
43. Murthy S.B., Patnana S.V., Xiao L., et al. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. Oncology 2010, 78:316-322.
44. Monjazeb A.M., Riedlinger G., Aklilu M., et al. Outcomes of patients with esophageal cancer staged with [(1)F]fluorodeoxyglucose positron emission tomography (FDG-PET): Can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol 2010, 28:4714-4721.
45. Mamede M., El Fakhri G., Abreu-e-Lima P., et al. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med 2007, 21:553-562.
46. Jeganathan R., McGuigan J., Campbell F., et al. Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?. Eur J Nucl Med Mol Imaging 2011, 38:656-662.
47. Vali F.S., Nagda S., Hall W., et al. Comparison of standardized uptake value-based positron emission tomography and computed tomography target volumes in esophageal cancer patients undergoing radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1057-1063.
48. Muijs C.T., Beukema J.C., Pruim J., et al. A systematic review on the role of FDG-PET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol 2010, 97:165-171.
49. Leong T., Everitt C., Yuen K., et al. A prospective study to evaluate the impact of FDG-PET on CT-based radiotherapy treatment planning for oesophageal cancer. Radiother Oncol 2006, 78:254-261.
50. Moureau-Zabotto L., Touboul E., Lerouge D., et al. Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. Int J Radiat Oncol Biol Phys 2005, 63:340-345.
51. Muijs C.T., Schreurs L.M., Busz D.M., et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for esophageal cancer. Radiother Oncol 2009, 93:447-453.
52. PET-CT based radiotherapy in esophageal cancer patients ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01156831.